Literature DB >> 1720302

Characterization of purified gp 51 from bovine leukemia virus integrated into iscom. Physicochemical properties and serum antibody response to the integrated gp51.

M Merza1, J Söber, B Sundquist, I Toots, B Morein.   

Abstract

It is proposed that the envelope glycoprotein, gp 51, is the protective antigen of bovine leukemia virus (BLV). An experimental iscom vaccine has been prepared from immunoaffinity purified gp 51. To overcome the problem of integrating a nonamphipathic protein, gp 51 was partially denatured at pH 2.4 before integration into the iscom. The recovery of gp 51 into the iscom was calculated to be 85%. The gp 51 incorporated into iscom retained its physicochemical properties and the neutralizing epitopes F, G and H were found to be intact. The iscom preparation was shown to induce a specific immune response to gp 51 after inoculation into mice and calves, as tested by ELISA and Western blotting. Sera from the immunized calves specifically inhibited the VSV-(BLV) pseudotypes. Thus the gp 51-iscom preparations appear to be highly immunogenic and to induce a gp 51 specific response.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1720302     DOI: 10.1007/bf01310477

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  27 in total

1.  A method for determining the sedimentation behavior of enzymes: application to protein mixtures.

Authors:  R G MARTIN; B N AMES
Journal:  J Biol Chem       Date:  1961-05       Impact factor: 5.157

2.  Evaluation of an inactivated bovine leukemia virus preparation as an immunogen in cattle.

Authors:  J M Miller; M J Van Der Maaten
Journal:  Ann Rech Vet       Date:  1978

3.  Replication of bovine leukemia virus in monolayer cell cultures.

Authors:  M J Van Der Maaten; J M Miller
Journal:  Bibl Haematol       Date:  1975-10

4.  Pseudotype particles of vesicular stomatitis virus with surface antigens of bovine leukaemia virus--VSV (BLV) -- as a sensitive probe for detecting antibodies in the sera of spontaneously infected cattle.

Authors:  J Závada; L Cerný; A D Altstein; Z Závadová
Journal:  Acta Virol       Date:  1978-03       Impact factor: 1.162

5.  Topographical analysis by monoclonal antibodies of BLV-gp51 epitopes involved in viral functions.

Authors:  C Bruck; D Portetelle; A Burny; J Zavada
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

6.  Detection by immunodiffusion- and radioimmunoassay-tests of antibodies to bovine leukemia virus antigens in sera of experimentally infected sheep and cattle.

Authors:  M Mammerickx; D Portetelle; A Burny; J Leunen
Journal:  Zentralbl Veterinarmed B       Date:  1980

7.  Vaccination of cattle with binary ethylenimine-treated bovine leukemia virus.

Authors:  J M Miller; M J Van der Maaten; M J Schmerr
Journal:  Am J Vet Res       Date:  1983-01       Impact factor: 1.156

Review 8.  Bovine leukaemia virus and enzootic bovine leukosis.

Authors:  A Burny; C Bruck; Y Cleuter; D Couez; J Deschamps; D Gregoire; J Ghysdael; R Kettmann; M Mammerickx; G Marbaix
Journal:  Onderstepoort J Vet Res       Date:  1985-09       Impact factor: 1.792

9.  Bovine leukaemia virus ISCOMs: biochemical characterization.

Authors:  M S Merza; T Linné; S Höglund; D Portetelle; A Burny; B Morein
Journal:  Vaccine       Date:  1989-02       Impact factor: 3.641

10.  Monoclonal antibodies define eight independent antigenic regions on the bovine leukemia virus (BLV) envelope glycoprotein gp51.

Authors:  C Bruck; S Mathot; D Portetelle; C Berte; J D Franssen; P Herion; A Burny
Journal:  Virology       Date:  1982-10-30       Impact factor: 3.616

View more
  3 in total

1.  Polyclonal bovine sera but not virus-neutralizing monoclonal antibodies block bovine leukemia virus (BLV) gp51 binding to recombinant BLV receptor BLVRcp1.

Authors:  O Orlik; J Ban; J Hlavaty; C Altaner; R Kettmann; D Portetelle; G A Splitter
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

Review 2.  Preventive and therapeutic strategies for bovine leukemia virus: lessons for HTLV.

Authors:  Sabrina M Rodríguez; Arnaud Florins; Nicolas Gillet; Alix de Brogniez; María Teresa Sánchez-Alcaraz; Mathieu Boxus; Fanny Boulanger; Gerónimo Gutiérrez; Karina Trono; Irene Alvarez; Lucas Vagnoni; Luc Willems
Journal:  Viruses       Date:  2011-07-19       Impact factor: 5.048

3.  Veterinary vaccines.

Authors:  L A Babiuk; A A Potter
Journal:  Biotechnol Adv       Date:  1994       Impact factor: 14.227

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.